


Introduction

Background 5q-linked spinal muscular atrophy (SMA), is a monogenic neuromuscular disorder caused by mutations of *SMN1*, which encodes the ubiquitously expressed and multifunctional SMN protein. Although SMN-restoring gene therapies have been available since 2016, treated patients continue to exhibit symptoms or even disabilities, and it is yet unclear which SMN-related molecular pathways and cellular processes are the major drive of neurodegeneration.


Objective Using CRISPR/Cas9 mediated gene knockout, we aimed to generate a novel zebrafish model for SMA and to identify potential therapeutic pathways through transcriptomics study.

Genetic basis of SMA




The generation of a novel zebrafish crisprant model


Double-sgRNA knockout strategy




Genotype-phenotype correlation



SMN1 KO resulted in disease-relevant phenotypes




Characterization of motor neuron phenotype




Transcriptomics revealed calcium signaling alterations


Top transcriptomic pathways (IPA)



Major pathways of interest




Splicing analysis




CaMK targeting compound X showed rescue effects

Mitochondrial functional analysis (Seahorse XF)



Evaluation of locomotor phenotype



Conclusion and Discussion

- ✓ By targeting the zebrafish *SMN1* exon 7 for CRISPR/Cas9 knockout, we generated a robust crisprant model with well-characterized locomotor deficits and motor neuron defects.
- ✓ Bulk RNA-seq revealed that despite using whole embryo samples, the *SMN1* KO model is highly representative of neurological disorder and neuronal alterations.
- ✓ Based on transcriptomics, novel pathways of interest are mitochondrial dysfunction, calcium signaling and CREB signaling, with CaMK at the crossroads of these 3 pathways.
- ❑ We currently focus on investigating the connection between calcium signaling alterations and mitochondrial dysfunction through exploring a CaMK-mediated therapeutic pathway.

Discussion Zebrafish is an efficient model organism to study genetic diseases, but in the context of SMA, there is only *SMN1* but not its paralogous gene *SMN2* in the zebrafish genome. To bring to light the effect of CaMK-mediated therapeutic pathway on *SMN2* splicing, we will incorporate drug testing on SMA patient iPSC-derived motor neurons using different compounds, evaluating (1) motor neuron survival; (2) neuritic network; (3) CaMK level; (4) SMN level; (5) *SMN2* splicing.

Acknowledgement This work is supported by SMA Europe and Fondation Recherche Alzheimer.